Homepage Top Section2

The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has

Leqselvi is an oral drug that selectively inhibits Janus kinases JAK1 and JAK2. It has been approved for adult patients experiencing severe forms of alopecia areata, an autoimmune

Golden Age Health (GAH) has secured exclusive rights to commercialise and promote Innostellar Biotherapeutics’ first-in-class gene therapy candidate, LX-101, in mainland China. This ten-year Promotional Services Agreement leverages

This partnership will combine the OligoCreator technology of Secarna with Vect-Horus’ VECTrans system. The alliance uses Vect-Horus’ expertise in delivering compounds across biological barriers using its VECTrans platform.

This application aims to secure approval for treating adult and adolescent atopic dermatitis (AD). Under the partnership agreement, Connect Biopharma will receive up to approximately $110m in milestone

The deal, valued at up to $25m, includes an upfront equity payment of $7.5m and near-term milestones, extending Rallybio’s cash runway into mid-2027. The REV102 programme originated from

  Through this partnership, Sagent will gain sole rights to commercialise a select portfolio of Qilu’s complex injectable products in the US. These products encompass high-impact therapeutic areas,

The new facility is claimed to enhance Biosynth’s ability to manufacture GMP bioconjugates, supporting the production of intermediates and active pharmaceutical ingredients from early clinical stages till late-phase

Tyzavan is indicated for the treatment of several serious infections in adults and children one month and above, including septicemia, infective endocarditis, skin and skin structure infections, bone